Literature DB >> 26380542

Cardiomyopathies in Noonan syndrome and the other RASopathies.

Bruce D Gelb1, Amy E Roberts2, Marco Tartaglia3.   

Abstract

Noonan syndrome and related disorders (Noonan syndrome with multiple lentigines, Costello syndrome, cardiofaciocutaneous syndrome, Noonan syndrome with loose anagen hair, and other related traits) are autosomal dominant traits. Mutations causing these disorders alter proteins relevant for signaling through RAS. Thus, these traits are now collectively called the RASopathies. While the RASopathies have pleiomorphic features, this review will focus on the hypertrophic cardiomyopathy observed in varying percentages of all of these traits. In addition, inherited abnormalities in one pathway gene, RAF1, cause pediatric-onset dilated cardiomyopathy. The pathogeneses for the RASopathy-associated cardiomyopathies are being elucidated, principally using animal models, leading to genotype-specific insights into how signal transduction is perturbed. Based on those findings, small molecule therapies seem possible for RASopathy-associated cardiomyopathies.

Entities:  

Year:  2015        PMID: 26380542      PMCID: PMC4568836          DOI: 10.1016/j.ppedcard.2015.01.002

Source DB:  PubMed          Journal:  Prog Pediatr Cardiol        ISSN: 1058-9813


  40 in total

1.  Reduced phosphatase activity of SHP-2 in LEOPARD syndrome: consequences for PI3K binding on Gab1.

Authors:  Nadine Hanna; Alexandra Montagner; Wen Hwa Lee; Maria Miteva; Michel Vidal; Michel Vidaud; Béatrice Parfait; Patrick Raynal
Journal:  FEBS Lett       Date:  2006-04-12       Impact factor: 4.124

2.  PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.

Authors:  Maria I Kontaridis; Kenneth D Swanson; Frank S David; David Barford; Benjamin G Neel
Journal:  J Biol Chem       Date:  2005-12-23       Impact factor: 5.157

3.  An infant with Costello syndrome complicated with fatal hypertrophic obstructive cardiomyopathy.

Authors:  H Tomita; S Fuse; K Ikeda; K Matsuda; S Chiba
Journal:  Acta Paediatr Jpn       Date:  1998-12

4.  Survival implications: hypertrophic cardiomyopathy in Noonan syndrome.

Authors:  Edward J Hickey; Rohit Mehta; Maryam Elmi; Kentaro Asoh; Brian W McCrindle; William G Williams; Cedric Manlhiot; Lee Benson
Journal:  Congenit Heart Dis       Date:  2011 Jan-Feb       Impact factor: 2.007

5.  Congenital heart diseases in children with Noonan syndrome: An expanded cardiac spectrum with high prevalence of atrioventricular canal.

Authors:  B Marino; M C Digilio; A Toscano; A Giannotti; B Dallapiccola
Journal:  J Pediatr       Date:  1999-12       Impact factor: 4.406

6.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention.

Authors:  Barry J Maron; Jeffrey A Towbin; Gaetano Thiene; Charles Antzelevitch; Domenico Corrado; Donna Arnett; Arthur J Moss; Christine E Seidman; James B Young
Journal:  Circulation       Date:  2006-03-27       Impact factor: 29.690

7.  The natural history of Noonan syndrome: a long-term follow-up study.

Authors:  A C Shaw; K Kalidas; A H Crosby; S Jeffery; M A Patton
Journal:  Arch Dis Child       Date:  2006-09-21       Impact factor: 3.791

8.  MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation.

Authors:  Xue Wu; Jeremy Simpson; Jenny H Hong; Kyoung-Han Kim; Nirusha K Thavarajah; Peter H Backx; Benjamin G Neel; Toshiyuki Araki
Journal:  J Clin Invest       Date:  2011-02-21       Impact factor: 14.808

9.  Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.

Authors:  Alessandra Fragale; Marco Tartaglia; Jie Wu; Bruce D Gelb
Journal:  Hum Mutat       Date:  2004-03       Impact factor: 4.878

10.  Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene.

Authors:  Maria Cristina Digilio; Emanuela Conti; Anna Sarkozy; Rita Mingarelli; Tania Dottorini; Bruno Marino; Antonio Pizzuti; Bruno Dallapiccola
Journal:  Am J Hum Genet       Date:  2002-06-07       Impact factor: 11.025

View more
  29 in total

1.  Costello syndrome: Clinical phenotype, genotype, and management guidelines.

Authors:  Karen W Gripp; Lindsey A Morse; Marni Axelrad; Kathryn C Chatfield; Aaron Chidekel; William Dobyns; Daniel Doyle; Bronwyn Kerr; Angela E Lin; David D Schwartz; Barbara J Sibbles; Dawn Siegel; Suma P Shankar; David A Stevenson; Mihir M Thacker; K Nicole Weaver; Sue M White; Katherine A Rauen
Journal:  Am J Med Genet A       Date:  2019-06-20       Impact factor: 2.802

2.  Characteristic MR Imaging Findings of the Neonatal Brain in RASopathies.

Authors:  M N Cizmeci; M Lequin; K D Lichtenbelt; D Chitayat; P Kannu; A G James; F Groenendaal; E Chakkarapani; S Blaser; L S de Vries
Journal:  AJNR Am J Neuroradiol       Date:  2018-04-05       Impact factor: 3.825

Review 3.  Genetic Basis for Congenital Heart Disease: Revisited: A Scientific Statement From the American Heart Association.

Authors:  Mary Ella Pierpont; Martina Brueckner; Wendy K Chung; Vidu Garg; Ronald V Lacro; Amy L McGuire; Seema Mital; James R Priest; William T Pu; Amy Roberts; Stephanie M Ware; Bruce D Gelb; Mark W Russell
Journal:  Circulation       Date:  2018-11-20       Impact factor: 29.690

4.  When and why is surgical revascularization indicated for the treatment of moyamoya syndrome in patients with RASopathies? A systematic review of the literature and a single institute experience.

Authors:  Marcello Scala; Pietro Fiaschi; Valeria Capra; Maria Luisa Garrè; Domenico Tortora; Marcello Ravegnani; Marco Pavanello
Journal:  Childs Nerv Syst       Date:  2018-05-24       Impact factor: 1.475

5.  Congenital heart defects in Noonan syndrome: Diagnosis, management, and treatment.

Authors:  Léa Linglart; Bruce D Gelb
Journal:  Am J Med Genet C Semin Med Genet       Date:  2020-02-05       Impact factor: 3.908

Review 6.  Pediatric Cardiomyopathies.

Authors:  Teresa M Lee; Daphne T Hsu; Paul Kantor; Jeffrey A Towbin; Stephanie M Ware; Steven D Colan; Wendy K Chung; John L Jefferies; Joseph W Rossano; Chesney D Castleberry; Linda J Addonizio; Ashwin K Lal; Jacqueline M Lamour; Erin M Miller; Philip T Thrush; Jason D Czachor; Hiedy Razoky; Ashley Hill; Steven E Lipshultz
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

Review 7.  Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.

Authors:  Ali J Marian; Eugene Braunwald
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

8.  Development of Noonan syndrome by deregulation of allosteric SOS autoactivation.

Authors:  Hope Gloria Umutesi; Hanh My Hoang; Hope Elizabeth Johnson; Kwangho Nam; Jongyun Heo
Journal:  J Biol Chem       Date:  2020-08-04       Impact factor: 5.157

9.  The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathway.

Authors:  David A Stevenson; Lisa Schill; Lisa Schoyer; Brage S Andresen; Annette Bakker; Pinar Bayrak-Toydemir; Emma Burkitt-Wright; Kathryn Chatfield; Florent Elefteriou; Ype Elgersma; Michael J Fisher; David Franz; Bruce D Gelb; Anne Goriely; Karen W Gripp; Antonio Y Hardan; Kim M Keppler-Noreuil; Bronwyn Kerr; Bruce Korf; Chiara Leoni; Frank McCormick; Scott R Plotkin; Katherine A Rauen; Karlyne Reilly; Amy Roberts; Abby Sandler; Dawn Siegel; Karin Walsh; Brigitte C Widemann
Journal:  Am J Med Genet A       Date:  2016-05-07       Impact factor: 2.802

10.  De novo RRAGC mutation activates mTORC1 signaling in syndromic fetal dilated cardiomyopathy.

Authors:  Michael T Zimmermann; Maengjo Kim; Pamela A Long; Jared M Evans; Xiaolei Xu; Timothy M Olson
Journal:  Hum Genet       Date:  2016-05-27       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.